{
    "organizations": [],
    "uuid": "5583b36c79c88ced24ecafe7e8c506ce0f280328",
    "author": "",
    "url": "https://www.reuters.com/article/brief-agios-outlines-key-2018-priorities/brief-agios-outlines-key-2018-priorities-expanding-clinical-and-research-programs-to-drive-long-term-value-idUSFWN1P30J1",
    "ord_in_thread": 0,
    "title": "BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 20 PM / Updated 17 minutes ago BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value Reuters Staff \nJan 8 (Reuters) - Agios Pharmaceuticals Inc: \n* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE \n* AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018 \n* AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019 \n* AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018 \n* AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018 \n* AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018 Source text for Eikon:  ",
    "published": "2018-01-08T14:19:00.000+02:00",
    "crawled": "2018-01-08T14:40:00.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "outline",
        "key",
        "priority",
        "expanding",
        "clinical",
        "research",
        "program",
        "drive",
        "long",
        "term",
        "value",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "agio",
        "pharmaceutical",
        "inc",
        "agio",
        "outline",
        "key",
        "priority",
        "expanding",
        "clinical",
        "research",
        "program",
        "drive",
        "long",
        "term",
        "value",
        "agio",
        "pharmaceutical",
        "inc",
        "seventh",
        "ind",
        "submission",
        "dhodh",
        "inhibitor",
        "treatment",
        "hematologic",
        "malignancy",
        "expected",
        "4q",
        "agio",
        "year",
        "end",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "568m",
        "fund",
        "expanded",
        "clinical",
        "research",
        "program",
        "end",
        "3q",
        "agio",
        "pharmaceutical",
        "inc",
        "two",
        "pivotal",
        "trial",
        "pyruvate",
        "kinase",
        "deficiency",
        "initiate",
        "1q",
        "activate",
        "2q",
        "agio",
        "pharmaceutical",
        "inc",
        "phase",
        "proof",
        "concept",
        "trial",
        "thalassemia",
        "planned",
        "4q",
        "agio",
        "pharmaceutical",
        "inc",
        "mat2a",
        "inhibitor",
        "expected",
        "enter",
        "phase",
        "trial",
        "tumor",
        "1q",
        "source",
        "text",
        "eikon"
    ]
}